ATE521631T1 - USE OF AIMP2DX2 TO DIAGNOSE AND TREAT CANCER - Google Patents

USE OF AIMP2DX2 TO DIAGNOSE AND TREAT CANCER

Info

Publication number
ATE521631T1
ATE521631T1 AT05819055T AT05819055T ATE521631T1 AT E521631 T1 ATE521631 T1 AT E521631T1 AT 05819055 T AT05819055 T AT 05819055T AT 05819055 T AT05819055 T AT 05819055T AT E521631 T1 ATE521631 T1 AT E521631T1
Authority
AT
Austria
Prior art keywords
aimp2dx2
diagnose
treat cancer
aimp2
cancer
Prior art date
Application number
AT05819055T
Other languages
German (de)
Inventor
Sunghoon Kim
Original Assignee
Neomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomics Co Ltd filed Critical Neomics Co Ltd
Priority claimed from PCT/KR2005/003924 external-priority patent/WO2006057500A1/en
Application granted granted Critical
Publication of ATE521631T1 publication Critical patent/ATE521631T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung

Abstract

The present invention relates to a variant of AIMP2 lacking exon 2, named as AIMP2-DX2, which is specifically expressed in cancer cells. The AIMP2-DX2 protein and gene can be successfully used in the development of diagnosis and treatment of cancer.
AT05819055T 2004-11-24 2005-11-18 USE OF AIMP2DX2 TO DIAGNOSE AND TREAT CANCER ATE521631T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040097164 2004-11-24
KR1020050039073A KR20060057992A (en) 2004-11-24 2005-05-10 P38-dx2 and its use
PCT/KR2005/003924 WO2006057500A1 (en) 2004-11-24 2005-11-18 Use of aimp2dx2 for the diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
ATE521631T1 true ATE521631T1 (en) 2011-09-15

Family

ID=37153221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819055T ATE521631T1 (en) 2004-11-24 2005-11-18 USE OF AIMP2DX2 TO DIAGNOSE AND TREAT CANCER

Country Status (5)

Country Link
JP (1) JP4718556B2 (en)
KR (1) KR20060057992A (en)
CN (1) CN101087804B (en)
AT (1) ATE521631T1 (en)
ES (1) ES2371479T3 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
CN102985103A (en) * 2010-05-04 2013-03-20 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
US20160038573A1 (en) * 2013-01-17 2016-02-11 Sit-Soft Intelligent Therapeutics Gmbh & Co. Kg Selective cell-death-inducing binary enzyme system
KR102297505B1 (en) * 2016-03-07 2021-09-01 재단법인 의약바이오컨버젼스연구단 Methods for screening anti-cancer drugs inhibiting interactions between AIMP2-DX2 and HSP70
KR101831435B1 (en) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Antibodies specifically binding to AIMP2-DX2 protein
EP3375871A1 (en) * 2017-03-13 2018-09-19 SIT Biotech GmbH Selective cell death-inducing enzyme system
KR102248420B1 (en) * 2019-03-15 2021-05-06 주식회사 제너로스 Recombinant vector containing target sequence for miR-142-3p

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100575251B1 (en) * 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 Pharmaceutical composition for treatment of cancer containing p38/JTV-1 as an effective component and screening method for pharmaceutical composition for treatment of cancer

Also Published As

Publication number Publication date
KR20060057992A (en) 2006-05-29
JP2008521398A (en) 2008-06-26
ES2371479T3 (en) 2012-01-03
CN101087804A (en) 2007-12-12
CN101087804B (en) 2012-07-04
JP4718556B2 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
ATE489957T1 (en) AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
ATE521631T1 (en) USE OF AIMP2DX2 TO DIAGNOSE AND TREAT CANCER
ATE542536T1 (en) 3-Ä4-(DIBENZOÄB,FÜÄ1,4ÜOXAZEPINE-11-YL)-PIPERAZI - 1-YLÜ-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
ATE526991T1 (en) COMPOSITIONS AND THEIR USES FOR THE GENETHERAPEUTIC TREATMENT OF BONE DISEASES
EA200700175A1 (en) COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY DISEASES
DE602005026866D1 (en) USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE
ATE506951T1 (en) TERTIARY CARBINAMINES ACTIVE AS INHIBITORS OF BETA-SECRETASE WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE602006017071D1 (en) COMPOSITIONS AND METHODS OF TREATING HEART DISEASES
ATE544748T1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
ATE501718T1 (en) USE OF BENZOCONDENSED HETEROCYCLIC SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER
DE602006012013D1 (en) PROTEASOME HEMMER AND USE METHOD THEREFOR
ATE399014T1 (en) NUCLEIC ACIDS FOR THE TREATMENT OF DISEASES RELATED TO HMGB1
ATE453653T1 (en) PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS
ATE295735T1 (en) USE OF INTERLEUKIN-6 ANTAGONISTS TO TREAT ESTROGEN-DEPENDENT CANCER
NO20055741L (en) New chemical compounds
EA200600424A1 (en) APPLICATION OF POLYPEPTIDES OF THE FAMILY OF KUPREDOXINS IN TREATMENT OF CANCER
DE602005007220D1 (en) TETRAHYDROPYRIDOTHIOPHENES USE IN THE TREATMENT OF CANCER
DE602005023468D1 (en) USE OF DENTAL FIBROBLASTES FOR THE TREATMENT OF VASCULAR CELLS
DE602006016333D1 (en) AZAXANTHONES FOR THE TREATMENT OF TUMORS
ATE465413T1 (en) USE OF ADAM 12 TO DIAGNOSE PREECLAMPSIA
DE602006016106D1 (en) COMPOSITIONS AND METHOD FOR PREDICTING THE OUTPUT OF TREATMENT
DE602005015434D1 (en) MEANS FOR THE TREATMENT OF PSYCHONEUROTIC DISEASES
DE60313803D1 (en) CATHEPSINCYSTEIN PROTEASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND IMMUNE DISEASES

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties